ArticleFrontiers in oncology2025

Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database.

Yu Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.